CANNABIMATCH is a vertically-integrated company dedicated to the research and development of novel and proprietary cannabinoid-based treatment options for unmet medical needs.
As part of our efforts to advance the knowledge about medical cannabis for the benefit of patients in-need, we are proud to present the “CANNABIMATCH Program for Medical Cannabis Knowledge Mobilization”.
While medical cannabis programs are emerging around the world, the integration of cannabis into the clinical practice remains heavily challenged. Main reasons include the lack of scientific evidence (controlled studies) to support the therapeutic properties of cannabis, the lack of standardized products, and the herbal nature of cannabis which results in considerable variability within the available products.
To overcome these challenges, CANNABIMATCH’s core mission is to be engaged in R&D efforts in order to introduce medical-grade product candidates that are predictable and consistent, organic-plant-derived and meet pharmaceutical and regulatory quality standards. By utilizing our unique R&D capabilities, we are aiming to unravel the immense potential of cannabinoids.
While our R&D is underway, many patients are suffering NOW. It is thus essential to allow access for medical cannabis products to patients in various ailments and diseases whose conditions have not been improved sufficiently from traditional medications. Nevertheless, many healthcare providers are reluctant to allow their patients to use medical cannabis.
The medical cannabis program in Israel was established during the late 1990s, and it is one of oldest around the world. The number of patients who hold a governmental license for medical cannabis has grown exponentially during the last decade, and it is currently estimated to be over 50,000. Israel additionally stands in the forefront of the research related to medical cannabis and to cannabinoids. As a result, there are a few Israeli physicians who gained substantial knowledge accumulated during many years of clinical experience with hundreds (or thousands) of patients treated with medical cannabis.
In Israel physicians are eligible to recommend medical cannabis only within their medical specialty. This means, for example, that psychiatrists are only allowed to recommend medical cannabis to patients with mental disorders, etc. While this requirement may be considered as a regulatory burden, on the other hand it facilitated the formation of explicit expertise by few physicians who acknowledge the therapeutic potential of medical cannabis to their patients while nurturing compassion, innovation, integrity and professionalism.
The “CANNABIMATCH Program for Medical Cannabis Knowledge Mobilization” aims to utilize the vast clinical knowledge of such Israeli physicians for assisting physicians and other healthcare providers in other places who wish to integrate medical cannabis into their clinical practice. In the first phase for the program, the focus will be set on mental and behavioral disorders, and more specifically on post-traumatic stress disorder (PTSD) and autism.
We believe that physicians and patients alike may benefit from knowledge-based clinical guidelines which provide explicit answers to issues that physicians often confront with in relation to medical cannabis, such as patient selection and screening, tailored treatment plans (products selection and dosing recommendations), red-flags and follow-up protocols.